Pages that link to "Q44542155"
Jump to navigation
Jump to search
The following pages link to The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events (Q44542155):
Displaying 50 items.
- A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity (Q24615651) (← links)
- Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance (Q28191924) (← links)
- Peptic ulcer disease today (Q28194844) (← links)
- Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies (Q28200569) (← links)
- Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study (Q28211313) (← links)
- Selective COX-2 inhibitors: do they retain any gastroduodenal toxicity (Q28212914) (← links)
- Dynamic simulations on the arachidonic acid metabolic network (Q28221357) (← links)
- Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin. (Q30248439) (← links)
- Etoricoxib: a highly selective COX-2 inhibitor (Q33213983) (← links)
- Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004–2008 – a retrospective patient record review (Q34418355) (← links)
- Etoricoxib and the treatment of ankylosing spondylitis (Q34466689) (← links)
- Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis (Q34548071) (← links)
- Clinical pharmacology of etoricoxib (Q34570225) (← links)
- Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis (Q34610283) (← links)
- Epidemiology and Demographics of Upper Gastrointestinal Bleeding: Prevalence, Incidence, and Mortality (Q34632574) (← links)
- Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. (Q35048654) (← links)
- Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway (Q35098611) (← links)
- Etoricoxib for arthritis and pain management (Q35166773) (← links)
- The role of cyclooxygenase selective inhibitors in the gastrointestinal tract (Q35577387) (← links)
- Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials (Q35680546) (← links)
- An evidence-based update on nonsteroidal anti-inflammatory drugs (Q35758411) (← links)
- Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease (Q35939955) (← links)
- Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis (Q35954438) (← links)
- Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials (Q36013803) (← links)
- Are rates of gastrointestinal bleeding higher following the introduction of COX-2 inhibitors? (Q36150589) (← links)
- Selective COX-2 inhibitors and risk of myocardial infarction (Q36173750) (← links)
- Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury (Q36195392) (← links)
- Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? (Q36360540) (← links)
- NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options (Q36384721) (← links)
- Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty? (Q36721990) (← links)
- Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib (Q37175779) (← links)
- Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors (Q37385351) (← links)
- Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage (Q37476761) (← links)
- Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors (Q37893966) (← links)
- Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses (Q38993297) (← links)
- Efficacy and safety of etoricoxib in the treatment of osteoarthritis (Q39320502) (← links)
- Combination of etoricoxib and low-pressure pneumoperitoneum versus standard treatment for the management of pain after laparoscopic cholecystectomy: a randomized controlled trial. (Q40514029) (← links)
- Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study (Q41523582) (← links)
- Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). (Q41998132) (← links)
- Discovery of Dual Target Inhibitors against Cyclooxygenases and Leukotriene A4 Hydrolyase (Q42740984) (← links)
- Recent advances in endovascular techniques for management of acute nonvariceal upper gastrointestinal bleeding (Q42871830) (← links)
- Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis (Q43133532) (← links)
- Is There a Tension between Clinical Practice and Reimbursement Policy? The Case of Osteoarthritis Prescribing Practices in Ontario. (Q43178350) (← links)
- Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003? (Q44808671) (← links)
- Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. (Q44971339) (← links)
- Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs (Q45868063) (← links)
- Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects (Q46628463) (← links)
- Time course and pattern of blood loss with ibuprofen treatment in healthy subjects (Q46791645) (← links)
- Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis (Q46907611) (← links)
- Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly (Q47756560) (← links)